Increased risk of mycobacterial infections associated with anti-rheumatic medications

Thorax

Volumn 70, Issue 7, 2015, Pages 677-682

  Brode, Sarah K ^a,b,c   Jamieson, Frances B ^c,d   Ng, Ryan ^e   Campitelli, Michael A ^e   Kwong, Jeffrey C ^a,c,d,e   Paterson, J Michael ^e,f,g   Li, Ping ^e   Marchand Austin, Alex ^d   Bombardier, Claire ^f,h   Marras, Theodore K ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b WEST PARK HEALTHCARE CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PUBLIC HEALTH ONTARIO   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PRESCRIPTION DRUG; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; CANADA; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HUMAN; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPLICATION; DRUG UTILIZATION; FACTUAL DATABASE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; OPPORTUNISTIC INFECTIONS; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; ONTARIO; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939232128     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206470     Document Type: Article

References (35)

1. Spector TD Rheumatoid arthritis. Rheum Dis Clin North Am 1990; 16: 513-37.
2. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
3. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-94.
4. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-22.
5. Brode SK, Jamieson FB, Ng R, et al. Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. Chest 2014; 146: 563-72.
6. Wagner UG, Koetz K, Weyand CM, et al. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 1998; 95: 14447-52.
7. Fowler CJ, Olivier KN, Leung JM, et al. Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium. Am J Respir Crit Care Med 2013; 187: 1374-81.
8. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
9. Winthrop K, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72: 37-42.
10. Widdifield J, Bombardier C, Bernatsky S, et al. An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: the influence of the reference standard on algorithm performance. BMC Musculoskelet Disord 2014; 15: 216.
11. AlHouqani M, Jamieson F, Cheodore P, et al. Isolation prevalence of pulmonary nontuberculous mycobacteria in Ontario 2007. Can Respir J 2011; 18: 19-24.
12. Andrejak C, Thomsen VO, Johansen IS, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514-21.
13. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010; 182: 970-6.
14. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010; 182: 977-82.
15. Marras TK, Mehta M, Chedore P, et al. Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung 2010; 188: 289-99.
16. Winthrop KL, Baxter R, Liu L, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf 2011; 20: 229-35.
17. Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007; 131: 1166-72.
18. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178: 1066-74.
19. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 353-61.
20. Reid RJ, MacWilliam L, Verhulst L, et al. Performance of the ACG case-mix system in two Canadian provinces. Med Care 2001; 39: 86-99.
21. Hux JE, Ivis F, Flintoft V, et al. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002; 25: 512-16.
22. Vlasschaert MEO, Bejaimal SAD, Hackam DG, et al. Validity of administrative database coding for kidney disease: a systematic review. Am J Kidney Dis 2011; 57: 29-43.
23. Lopushinsky SR, Covarrubia KA, Rabeneck L, et al. Accuracy of administrative health data for the diagnosis of upper gastrointestinal diseases. Surg Endosc 2007; 21: 1733-7.
24. Gershon AS, Wang C, Guan J, et al. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD 2009; 6: 388-94.
25. Gershon AS, Wang C, Guan J, et al. Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J 2009; 16: 183-8.
26. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26: 734-53.
27. Brassard P, Lowe A-M, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009; 61: 300-4.
28. Dirac MA, Horan KL, Doody DR, et al. Environment or host?: a case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012; 186: 684-91.
29. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38: 1428-39.
30. Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008; 29: 283-94.
31. Kleinert S, Tony HP, Krueger K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-release assays under real-life conditions. Ann Rheum Dis 2012; 71: 1791-5.
32. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72.
33. Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med 2011; 105: 1718-25.
34. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69: 380-6.
35. Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012; 39: 1559-82.